Synthon’s SYD985 outperforms Roche’s Kadcyla, on to phase I
By Nuala Moran
Friday, April 4, 2014
LONDON – Synthon Biopharmaceuticals NV is making final preparations to advance its lead antibody drug conjugate (ADC) based on Herceptin (trastuzumab) into phase I, after completing a preclinical head-to-head comparison with the Herceptin ADC Kadcyla (ado-trastuzumab emtansine, T-DM1).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.